• Year Founded: 1993
• Headquarters: Beijing,China
• Estimated Employees: N/A
• Product Lines:
  • Human Vaccines
• Products:
  • Enterovirus Type 71 Vaccine (Vero Cell), Inactivated
  • Hepatitis A Vaccine (Human Diploid Cell), Inactivated
  • Combined Hepatitis A and Hepatitis B Vaccine
  • Influenza Vaccine (Split Virion), Inactivated
  • Pandemic Influenza Vaccine (inactivated, adjuvanted)
  • H1N1 Influenza A Vaccine

H1N1 Influenza A Vaccine(First pandemic influenza A (H1N1) vaccine approved globally)

Hepatitis A Vaccine (Human Diploid Cell), Inactivated(A WHO Prequalified Inactivated Hepatitis A Vaccine)

Pandemic Influenza Vaccine (inactivated, adjuvanted)

Sinovac was established in 1993, we engaged in the initial R&D activities that lead to the successful development of the Company’s hepatitis A vaccine in 1999. This is the first inactivated hepatitis A vaccine developed by Chinese scientists.

Over the past two decades, we have developed and commercialized six human-used vaccines and one animal vaccine, and advanced its R&D pipeline. We have developed the world's first inactivated SARS virus vaccine (completed phase I clinical), China's first pandemic influenza (H5N1) vaccine and the world's first influenza A (H1N1) vaccine.

Our 23-valent pneumococcal polysaccharide vaccine, Sabine strain-inactivated polio vaccine (sIPV) and tetravalent influenza virus split vaccine have started production. And the new coronavirus vaccine(COVID-19 vaccine), pneumococcal conjugate vaccine and multiple joint vaccine projects are in clinical or preclinical research.

Moreover, we expanded our fully integrated platform with state-of-the-art research facilities, GMP certified manufacturing facilities, and a sales team with reach across China. We are currently developing a novel vaccine against enterovirus 71, causing the severe hand, foot and mouth disease (HFMD) among the children.